Search Results - "PROW, D. M"

  • Showing 1 - 8 results of 8
Refine Results
  1. 1

    Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance) by Yoon, H.H., Foster, N.R., Meyers, J.P., Steen, P.D., Visscher, D.W., Pillai, R., Prow, D.M., Reynolds, C.M., Marchello, B.T., Mowat, R.B., Mattar, B.I., Erlichman, C., Goetz, M.P.

    Published in Annals of oncology (01-02-2016)
    “…Carboplatin (C) and paclitaxel (P) are standard treatments for carcinoma of unknown primary (CUP). Everolimus, an mTOR inhibitor, exhibits activity in diverse…”
    Get full text
    Journal Article
  2. 2

    Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours by FIZAZI, K, PROW, D. M, PAGLIARO, L. C, LOGOTHETIS, C. J, AMATO, R. J, DO, K-A, WANG, X, FINN, L, KIM, J, DALIANI, D, PAPANDREOU, C. N, TU, S-M, MILLIKAN, R. E

    Published in British journal of cancer (20-05-2002)
    “…Only about half of patients with a poor-prognosis non-seminomatous germ-cell tumours can achieve a cure. The aim of this phase II study was to assess the…”
    Get full text
    Journal Article
  3. 3

    Management consideration in nonpulmonary visceral metastatic seminoma of testis by Park, D S, Prow, D M, Amato, R J, Logothetis, C J

    Published in Journal of Korean medical science (01-08-1999)
    “…To develop a more appropriate therapeutic strategy for treatment of nonpulmonary visceral metastatic testicular seminoma based on the International Germ Cell…”
    Get full text
    Journal Article
  4. 4

    Mechanism of platelet activating factor-induced vascular leakage in the rat trachea by Kirsch, C M, Brokaw, J J, Prow, D M, White, G W

    Published in Experimental lung research (1992)
    “…Platelet activating factor (PAF) is a phospholipid mediator of inflammation and vascular leakage that may be important in the etiology of asthma. We and others…”
    Get more information
    Journal Article
  5. 5

    Germ cell tumors: staging, prognosis, and outcome by Prow, D M

    Published in Seminars in urologic oncology (01-05-1998)
    “…Germ cell tumors (GCT) remain the model for solid tumor therapy. Until 1997, GCT staging was based on individual institution systems, which limited comparison…”
    Get more information
    Journal Article
  6. 6

    Clinical characteristics of metachronous bilateral testicular tumors in the chemotherapeutic era by Park, D S, Prow, D M, Amato, R J, Ro, J Y, Logothetis, C J

    Published in Yonsei medical journal (01-04-1999)
    “…We wanted to present the results of our experience with bilateral testis tumor and to suggest the effects of chemotherapy in suppressing the development of…”
    Get full text
    Journal Article
  7. 7

    Effects of platelet-activating factor on vascular permeability and granulocyte recruitment in the rat trachea by Brokaw, J J, Prow, D M, Kirsch, C M, White, G W

    Published in Lung (01-12-1991)
    “…Platelet-activating factor (PAF) is a phospholipid mediator known to produce several features of airway inflammation. We examined the effects of intravenous…”
    Get full text
    Journal Article
  8. 8

    Paclitaxel-based chemotherapy for patients with refractory or relapsed nonseminomatous germ cell tumors by Amato, Robert J, Prow, Debra M

    “…Germ cell tumors have been the paradigm for successful solid tumor therapy. With multimodality treatment including surgery and/or chemotherapy and/or radiation…”
    Get full text
    Book Review Journal Article